Search

Your search keyword '"I. Kedar"' showing total 124 results

Search Constraints

Start Over You searched for: Author "I. Kedar" Remove constraint Author: "I. Kedar"
124 results on '"I. Kedar"'

Search Results

2. A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancer

4. Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic

5. Switching from Tacrolimus to Sirolimus Halts the Appearance of New Sebaceous Neoplasmsin Muir-Torre Syndrome

6. [Untitled]

7. Screening for Cytotoxic and Antimalarial Activities in Desert Plants of the Negev and Bedouin Market Plant Products

8. Dilemma of trisomy 20 mosaicism detected prenatally: Is it an innocent finding?

9. Elevated hCG as an isolated finding during the second trimester biochemical screen: genetic, ultrasonic, and perinatal significance

10. ARE ALL PHENOTYPICALLY-NORMAL TURNER SYNDROME FETUSES MOSAICS?

11. Differential Diagnosis and Management of Very Low Second Trimester Maternal Serum Unconjugated Estriol Levels, With Special Emphasis on the Diagnosis of X-Linked Ichthyosis

12. Fluorescent in-situ hybridization (FISH) as an aid to marker chromosome identification in prenatal diagnosis

13. Allogeneic Human Liposomal Melanoma Vaccine with or without IL-2 in Metastatic Melanoma Patients: Clinical and Immunobiological Effects

14. A negative second trimester triple test and absence of specific ultrasonographic markers may decrease the need for genetic amniocentesis in advanced maternal age by 60%

15. Replication asynchrony increases in women at risk for aneuploid offspring

16. Genetic diagnosis from formalin-fixed fetal tissue using FISH: a new tool for genetic counseling in subsequent pregnancies

17. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine

18. A noninvasive screening of systemic reactive (secondary) AA amyloidosis, based on reduced amyloid degrading activity of amyloidotic serum

25. THE PROTECTIVE EFFECT OF DIMETHYL SULFOXIDE IN EXPERIMENTAL ISCHEMIA OF THE INTESTINE

26. Growth regulation of transformed T cells by nonactivated macrophages: the role of Ia expression

27. The role of polymorphonuclear leucocytes and T lymphocytes in experimental murine amyloidosis

28. Treatment of experimental murine amyloidosis with dimethyl sulfoxide

30. Enhancement of Amyloid Degradation by Ascorbic Acid: In Vivo Evidence in a Murine Model

31. In vitro synthesis of 'amyloid'fibrils from insulin, calcitonin and parathormone

32. Alleviation of experimental ischemic acute renal failure by dimethyl sulfoxide

33. Degradation of amyloid by a serum component and inhibition of degradation

34. Dimethyl sulfoxide in acute ischemia of the kidney

35. Stimulation of murine amyloidosis by a dializable product from pretreated donors

36. Colchicine inhibition of casein-induced amyloidosis in mice

37. Regression of amyloidosis secondary to granulomatous ileitis following surgical resection and colchicine administration

39. Demonstration of amyloid-degrading activity in normal human serum

40. Inhibition of amyloid synthesis in experimental animals by a protein free diet. A preliminary report

42. Prolonged Colchicine Treatment in Four Patients with Amyloidosis

43. The genetic landscape of Lynch syndrome in the Israeli population.

44. BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.

45. A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies.

46. Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.

47. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants.

48. The Diagnostic Yield and Implications of Targeted Founder Pathogenic Variant Testing in an Israeli Cohort.

49. High prevalence of MUTYH associated polyposis among minority populations in Israel, due to rare founder pathogenic variants.

50. [GENOTYPE-PHENOTYPE CORRELATIONS BY SPECIFIC FOUNDER VARIANTS IN BRCA IN ISRAELI WOMEN].

Catalog

Books, media, physical & digital resources